Impact of estimated glomerular filtration rate on long-term clinical outcomes among Chinese patients with atrial fibrillation

Table 2 Clinical outcomes during the follow-up period

Outcomes	Total population n = 433	Individuals with VHDs		Individuals without VHDs n = 283	P-value
Outcomes	Total population n = 433	ERHA Type 1 n = 91	ERHA Type 2 n = 59	Individuals without VHDs n = 283	P-value
Death, n (%)	73 (16.9)	19 (20.9)	10 (16.9)	44 (15.5)	0.497
Heart failure, n (%)	24 (5.5)	1 (1.1)	7 (11.9)	16 (5.7)	0.019
ACS, n (%)	6 (1.4)	1 (1.1)	0 (0)	5 (1.8)	0.375
Hypotension, n (%)	3 (0.7)	0 (0)	0 (0)	3 (1.1)	0.278
TIA or Stroke, n (%)	39 (9.0)	6 (6.6)	1 (1.7)	32 (11.3)	0.042
VT or VF, n (%)	2 (0.5)	1 (1.1)	0 (0)	1 (0.4)	0.395
Others^a , n (%)	2 (0.5)	0 (0)	1 (1.7)	1 (0.4)	0.605

Median follow-up period 3.1 (0.5–4.5) years. VHD indicates valvular heart diseases
ACS acute coronary syndrome, TIA transient ischemic attack, VT ventricular tachycardia, VF ventricular fibrillation, AF atrial fibrillation
^aOthers includes 1 allergic dermatitis and 1 cholecystectomy

ISSN: 1471-2261